• 1. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

Comprehensive Analysis of 1,3-Bis(9H-carbazol-4-yloxy)-2-propanol (CAS No. 1276477-91-8): A Critical Carvedilol Impurity

1,3-Bis(9H-carbazol-4-yloxy)-2-propanol, identified by its CAS number 1276477-91-8, is a significant pharmaceutical impurity associated with the drug Carvedilol. This compound has garnered attention in the fields of pharmaceutical chemistry and drug safety due to its potential impact on the efficacy and stability of Carvedilol formulations. As a process-related impurity, it is often monitored during the drug manufacturing process to ensure compliance with stringent regulatory standards set by agencies such as the FDA and EMA.

The structural complexity of 1,3-Bis(9H-carbazol-4-yloxy)-2-propanol makes it a subject of interest for researchers focusing on impurity profiling and analytical method development. Its presence in Carvedilol formulations, even in trace amounts, can influence the drug's pharmacokinetics and therapeutic performance. Recent studies have highlighted the importance of chromatographic techniques, such as HPLC and LC-MS, in detecting and quantifying this impurity with high precision.

In the context of patient safety, understanding the role of Carvedilol Impurities like 1,3-Bis(9H-carbazol-4-yloxy)-2-propanol is crucial. The pharmaceutical industry is increasingly adopting Quality by Design (QbD) principles to minimize impurity formation during synthesis. This approach aligns with the growing demand for high-purity APIs (Active Pharmaceutical Ingredients) and the need to mitigate risks associated with degradation products.

From an environmental perspective, the disposal and management of pharmaceutical impurities like 1276477-91-8 are also under scrutiny. Researchers are exploring green chemistry alternatives to reduce the environmental footprint of drug manufacturing. This aligns with global trends toward sustainable pharmaceuticals and the reduction of hazardous waste in the industry.

The analytical characterization of 1,3-Bis(9H-carbazol-4-yloxy)-2-propanol often involves advanced spectroscopic methods, including NMR and FT-IR, to confirm its molecular structure. These techniques are essential for method validation and ensuring the accuracy of impurity detection. Additionally, computational tools like molecular modeling are being employed to predict the behavior of such impurities under various conditions.

As the pharmaceutical landscape evolves, the focus on impurity control and risk assessment continues to grow. 1,3-Bis(9H-carbazol-4-yloxy)-2-propanol serves as a case study for the challenges and solutions in managing drug impurities. Its study not only enhances our understanding of Carvedilol's stability but also contributes to broader discussions on pharmaceutical quality assurance and regulatory compliance.

For researchers and industry professionals, staying updated on the latest advancements in impurity analysis is vital. The development of robust analytical methods and the integration of cutting-edge technologies will play a pivotal role in addressing the challenges posed by compounds like 1,3-Bis(9H-carbazol-4-yloxy)-2-propanol. This underscores the importance of continuous innovation in the field of pharmaceutical sciences.

• 95093-95-1((S)-(+)-4-(2,3-Epoxypropoxy)carbazole)
• 61212-32-6(3-(1H-indol-4-yloxy)-1,2-Propanediol)
• 145679-40-9((R)-5-Oxiranylmethoxyquinoline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)